NASDAQ:URGN

Urogen Pharma Stock News

Healthcare > Biotechnology

Buy URGN

*Your capital is at risk

$26.60

+0.0600 (+0.226%)

At Close: Jun 03, 2026

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

08:00am, Monday, 03'rd Jun 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

08:00am, Wednesday, 22'nd May 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod

UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript

06:30pm, Monday, 13'th May 2024

UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chie

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

08:00am, Monday, 13'th May 2024

UroGen Pharma to Participate at Upcoming Investor Conferences

08:00am, Tuesday, 07'th May 2024

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

12:20pm, Sunday, 05'th May 2024

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

03:20pm, Saturday, 04'th May 2024

PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

11:50am, Saturday, 04'th May 2024

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

08:00am, Friday, 03'rd May 2024

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

12:02pm, Wednesday, 17'th Apr 2024

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

08:00am, Monday, 15'th Apr 2024

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

08:00am, Thursday, 14'th Mar 2024

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by